Phase II Study in Patients With Operable Breast Cancer
Public ClinicalTrials.gov record NCT00518583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu
Study identification
- NCT ID
- NCT00518583
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Aptium Oncology Research Network
- Network
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Pegylated Liposomal Doxorubicin (Doxil) Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2006
- Primary completion
- Dec 31, 2008
- Completion
- Aug 31, 2009
- Last update posted
- Jan 14, 2010
2006 – 2009
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence St. Joseph Medical Hospital | Burbank | California | 91505 | — |
| Cedars-Sinai Outpatient Cancer Center | Los Angeles | California | 90048 | — |
| Desert Regional Medical Center Comprehensive Cancer Center | Palm Springs | California | 92262 | — |
| Lynn Regional Cancer Center West | Boca Raton | Florida | 33486 | — |
| John H. Stroger, Jr. Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Maimonides Cancer Center | Brooklyn | New York | 11220 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| St Vincent Comprehensive Cancer Center | New York | New York | 10011 | — |
| University of Cincinnati | Cincinnati | Ohio | 45221 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00518583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2010 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00518583 live on ClinicalTrials.gov.